[{"id":"40bb0841-9ed0-42d9-907d-c61c03f571b6","acronym":"CISLD-8","url":"https://clinicaltrials.gov/study/NCT04418401","created_at":"2021-01-18T21:17:44.006Z","updated_at":"2024-07-02T16:35:45.868Z","phase":"Phase 1","brief_title":"Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients","source_id_and_acronym":"NCT04418401 - CISLD-8","lead_sponsor":"Zhejiang University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepsun (donafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-06-13"},{"id":"f27f8acd-53b5-4df1-933c-d12add91675c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493332","created_at":"2022-08-09T17:04:46.893Z","updated_at":"2024-07-02T16:36:05.229Z","phase":"Phase 2","brief_title":"HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC","source_id_and_acronym":"NCT05493332","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • oxaliplatin • leucovorin calcium • Zepsun (donafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2022-08-18"},{"id":"64058750-6a85-4e5f-b475-62227d43241d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05161143","created_at":"2021-12-17T17:31:03.532Z","updated_at":"2024-07-02T16:36:19.380Z","phase":"Phase 2","brief_title":"Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05161143","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepsun (donafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-12-17"}]